CSTL
What one share of Castle Biosciences holds
Services – Medical Laboratories
Castle Biosciences is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (“BE”), atopic dermatitis (“AD”), uveal melanoma (“UM”).
Castle Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $12.04 |
|---|---|
| Profit | −$0.65 |
| Capex (buildings and equipment) | $1.45 |
| Free cash flow | −$0.02 |
| Cash and investments | $8.75 |
| Debt | $0.34 |
| Book value | $15.41 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | $11.95 | −$5.33 | $0.15 | −$6.60 | $0.00 | −$29.52 |
| 2019 | $5.99 | −$0.21 | $0.11 | $0.70 | $0.00 | $4.97 |
| 2020 | $3.31 | −$0.54 | $0.25 | $0.27 | $0.00 | $16.75 |
| 2021 | $3.74 | −$1.24 | $0.14 | −$0.89 | $0.00 | $16.22 |
| 2022 | $5.26 | −$2.58 | $0.22 | −$1.81 | $0.00 | $15.03 |
| 2023 | $8.20 | −$2.14 | $0.51 | −$0.72 | $0.00 | $14.27 |
| 2024 | $11.35 | $0.62 | $0.97 | $1.25 | $0.00 | $16.00 |
| 2025 | $11.88 | −$0.83 | $1.24 | $0.98 | $0.00 | $15.86 |